Introduction
Small fibre neuropathy (SFN) is a peripheral neuropathy of the thinly myelinated A-fibres and unmyelinated C-fibres, and is associated with multiple underlying conditions Cazzato and Lauria, 2017; de Greef et al., 2018) . Patients suffer from excruciating pain and autonomic symptoms, leading to a significant negative impact on quality of life (Bakkers et al., 2014) .
In cases where an underlying condition is present, initial treatment usually focuses on this, but additional symptomatic therapy is generally needed. First-line treatment of neuropathic pain consists of tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin and gabapentin (Attal et al., 2010; Brouwer et al., 2015b; Finnerup et al., 2015) . However, the efficacy of these drugs is often unsatisfactory (Brouwer et al., 2015b; Finnerup et al., 2015) . Therefore, new treatment options are of great importance.
Voltage-gated sodium channels (VGSC; Na v s) underlie the initiation and propagation of action potentials in excitable membranes. Animal studies have shown that Na v s that are expressed in peripheral sensory neurons play important roles in neuropathic and inflammatory pain (Dib-Hajj et al., 2010) . Na v 1.7, Na v 1.8 and Na v 1.9, encoded by the genes SCN9A, SCN10A, and SCN11A, respectively, are preferentially expressed in dorsal root ganglion (DRG) neurons and their peripheral axons. Genetic and functional studies have shown that gain-of-function mutations in these genes cause human pain disorders (Dib-Hajj et al., 2017) . Gain-of-function mutations in Na v s have been reported in around 15% of patients with SFN (Brouwer et al., 2014; de Greef et al., 2018) , with SCN9A mutations being the most frequent. Taken together, inhibition of Na v s is expected to be therapeutically beneficial for pain patients (Dib-Hajj et al., 2010) .
Lacosamide is a functionalized amino acid that was thought to bind to the slow-inactivated state of Na v s (Amir et al., 2006; Beyreuther et al., 2007; Errington et al., 2008; Faber et al., 2012; Han et al., 2012a; Rogawski et al., 2015) . Recent data suggest that lacosamide binds to fast-inactivated Na v 1.7 with slower kinetics than classical sodium channel blockers (Jo and Bean, 2017) . Since pain in SFN is produced by inappropriate firing of DRG neurons (Brouwer et al., 2014; de Greef et al., 2018) , the Na v channels in these neurons would be expected to be in at least a partially inactivated state, so that lacosamide would be expected to bind with and inhibit these channels, thus attenuating the firing of DRG neurons. In addition, lacosamide has also been shown to modulate Na v 1.7 via regulation of collapsing response mediator protein 2 (CRMP2) (Dustrude et al., 2016) , which acts on multiple pathways involved in pain (Moutal et al., 2017) . The multi-modal action of lacosamide suggests that it might be effective in treating patients with Na v 1.7-related SFN.
To date, no studies with lacosamide in patients with SFN have been published. In studies with lacosamide in painful diabetic neuropathy a reduction in neuropathic pain was found, and the drug was well tolerated (Rauck et al., 2007; Shaibani et al., 2009; Wymer et al., 2009; Ziegler et al., 2010) , but the small number of patients in these cohorts, and the small numbers of patients and events for most outcomes led to the conclusion that lacosamide is not useful in treating neuropathic pain. The aim of our study was to evaluate the effect on pain, safety, and tolerability of lacosamide in painful peripheral neuropathy, with a specific focus on a well-defined group of patients with Na v 1.7-related SFN.
Materials and methods

Study design and participants
The Lacosamide-Efficacy-'N'-Safety in SFN (LENSS) study was a randomized, placebo-controlled, double-blind, crossoverdesign study. A detailed description of the study design was published previously (de Greef et al., 2016) ; a summary is given below.
All subjects were recruited at the Maastricht University Medical Center+ (Maastricht UMC+), the Netherlands, between November 2014 and July 2016, and data collection continued until May 2017. Patients were eligible if they had been diagnosed with pure SFN in combination with an SCN9A variant. According to the international guidelines, the diagnosis of pure SFN was based on typical clinical symptoms in combination with a diminished intra-epidermal nerve fibre density in skin biopsy and/or abnormal temperature threshold testing (Yarnitsky and Sprecher, 1994; Bakkers et al., 2015) without signs of large fibre involvement Cazzato and Lauria, 2017) . Patients with a history of associated conditions of SFN (except diabetes mellitus) were excluded for this study. Variants of the SCN9A gene were classified according to the Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in clinical Molecular Genetics (Wallis et al., 2013) . SFN patients with an SCN9A variant that was classified as class 3, 4, or 5 (variants of uncertain pathogenicity, variants likely to be pathogenic, and clearly pathogenic variants, respectively) were included (Wallis et al., 2013) . Where possible, in vitro confirmation of the functional effect of the mutation was performed and documented Brouwer et al., 2014) . All participants signed an informed consent form before entering the study. A detailed description of the inclusion and exclusion criteria was published elsewhere (de Greef et al., 2016) .
The study was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice Guidelines. The institutional Medical Ethics Committee approved the study protocol. The trial was registered under http://www.clinicaltrials.gov/, NCT01911975, as well as EudraCT, number 2013-001511-70.
Randomization and masking
From subjects who fulfilled the inclusion and exclusion criteria, baseline measurements were recorded. Randomization was performed by computer software called ALEA. Patients were stratified based on the type of SCN9A variant (genetically confirmed variant or genetically and functionally confirmed variant) and on the clinical diagnosis of SFN (abnormal skin biopsy, abnormal temperature threshold test, and abnormal skin biopsy in combination with an abnormal temperature threshold test). Patients were randomized into one of the two treatment arms, starting with lacosamide followed by placebo or starting with placebo followed by lacosamide. Because of the crossover design, patients completed two identical study periods, but in different arms. For subjects and investigators, the order in which patients received lacosamide and placebo, was blinded. Lacosamide and matching placebo were provided as 50 mg capsules for oral administration. The blinding codes were not broken during the entire study. Compliance and the use of rescue medication (acetaminophen) were recorded.
Procedures Figure 1 provides the study algorithm (de Greef et al., 2016) . In essence, each study part consisted of a titration period of 3 weeks, followed by a treatment period of 8 weeks, and a tapering period of 2 weeks. After a washout period of at least 2 weeks, the same schedule was repeated for the other arm. Four weeks after the last tapering period the study ended. During the 3-week titration period, patients received an increasing dose of lacosamide or placebo, starting with 50 mg twice daily (BID) in the first week, 100 mg BID in the second week, and 150 mg BID in the third week. Doses of 200 mg BID were then administered for 8 weeks. This part of the trial concluded with a 2-week tapering period, in which patients received 100 mg BID in the 12th week and 50 mg BID in the 13th week. At the beginning of each period (for example the titration period or treatment period), patients visited our centre. The unused study medication of the previous period was returned and the study medication for the next period was provided. Additionally, questionnaires were taken, blood tests and an ECG were performed. In between the visits, standardized check-up telephone calls were scheduled.
Outcome
The daily pain intensity numerical rating scale (PI-NRS) was used as the primary outcome measure according to the provided guidelines in painful neuropathic studies (Dworkin et al., 2008) . The PI-NRS consists of an 11-point numerical scale ranging from 0 to 10, where 0 represents no pain and 10 the worst pain possible. Subjects were asked to complete the PI-NRS twice daily, in the morning and evening at fixed time points. In addition to the PI-NRS, the daily sleep interference scale (DSIS) was completed every day on awakening. The DSIS consists of an 11-point numerical scale ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep). Additional questionnaires were completed at each visit that included the neuropathic pain scale (NPS), small fibre neuropathy symptom inventory questionnaire (SFN-SIQ), patients' global impression of change (PGIC), and the generic short-form SF-36 health survey (SF-36).
The primary efficacy outcome was at least a 1-point improvement (thus, reduction in score) on the PI-NRS compared to baseline, which is considered the minimum clinically important difference (MCID), according to unified rule of 0.5 Â standard deviation (SD) and the guidelines (Dworkin et al., 2008) .
Secondary outcomes were the proportion of patients having 52 points average pain improvement compared to their baseline PI-NRS scores, changes in the mean and maximum pain score on the PI-NRS, the NPS, DSIS, PGIC, SFN-SIQ, SF-36, adverse events, laboratory safety tests, blood pressure, pulse rate, and ECG. Sensitivity analyses included the 1-point and 2-point improvement from a less restricted baseline.
Statistical analyses
The sample size of 25 subjects was calculated with a response rate of 20% in the placebo group and 60% in the lacosamide group, a two-sided alpha of 5%, and an 80% power between the two groups ( 2 test), including the assumption of a dropout rate of 10%. An independent statistician was consulted and analysed the results after making some adjustments to the previously published statistical protocol (de Greef et al., 2016) .
The full analysis set consisted of all subjects who were randomized to receive study medication, regardless of whether or not they subsequently completed the study or deviated from the protocol. However, at least one measurement after taking the study medication should have been recorded. Subjects were analysed for efficacy according to randomized treatment. The full analysis set was used for all analyses of efficacy endpoints.
For all questionnaires, the difference between the baseline and treatment period was analysed. To determine the baseline of period 1, the last 14 days prior to randomization were taken. The interval for determining the period 2 baseline was the last 7 days of the washout period prior to commencing titration of the period 2 study medication. The comparator interval for the endpoint was the last 28 days of the respective treatment maintenance period.
For the primary efficacy endpoint (PI-NRS), each subject produced a baseline mean pain average and an ON treatment mean pain average. The average of non-missing day pain and night pain scores was derived. This was termed pain average. For example, if a night pain score was missing then the pain average equalled the day pain score. The difference between the average pain at baseline and after treatment was computed for each subject for each period. If for a given subject the change in mean pain average from ON treatment to period baseline was 4À1, then the subject was defined as a responder for that period. Any subject with missing change was defined as a non-responder for that period conditional upon that subject having commenced study treatment for that period. Otherwise their responder status was set to missing. In one of the secondary efficacy endpoints, a responder was defined as a subject whose pain was reduced by 2 or more points. Other secondary endpoints, the mean day and night pain, the maximum day and night pain and the maximum average pain were analysed, using these as a continuous variable. In the sensitivity analyses the 1-point and 2-point improvement were analysed with a less restricted baseline to include more information in the analyses.
Period 1 baseline was only calculated if the subject had recorded a pain score for at least 10 days of the 14-day baseline period. Period 2 baseline was only calculated if the subject had recorded a pain score for at least 5 days of the 7-day baseline period. A weekly pain score was only calculated if the subject had recorded a pain score for at least 4 days for that week. If the subject failed to meet these criteria the pain score was set to missing. Averages and maxima were calculated over available data. No data were imputed for missing observations. The DSIS outcome was derived for PI-NRS, where the changes from baseline were analysed as a continuous variable without dichotomization. The measurements at baseline and the last 28 days of the maintenance treatment period were compared.
For the other non-diary efficacy endpoints: NPS, PGIC, SFN-SIQ, and the SF-36, the period baselines were those assessed before the titration period of periods 1 and 2. The comparator assessment was taken at the end of the 8-week maintenance course of treatment. Changes from period baseline were derived. The 10 NPS subscales were calculated separately. For the PGIC, for each period a subject was coded to 'responder' if their response was either, 'minimally improved', 'much improved', or 'very much improved'. Missing values were coded to 'non-responders'. The SFN-SIQ sumscore was calculated. For the SF-36, absolute scores and changes from baseline for the different dimensions were analysed.
The safety set included all subjects in the full analysis set who received at least one dose of comparative study medication and had one measurement after taking medication. Subjects were analysed according to treatment received. The safety set was used for all analyses of safety endpoints.
The binary data for whether or not a subject was a responder were analysed using Generalized Estimating Equations (GEE) with treatment, period, period baseline, subject baseline, the stratification factors and interaction between treatment and period in the model. Subject was a random factor. The formal test of the primary hypothesis was conducted at the two-sided 5% level of significance. For continuous outcome variables, a mixed effect model was used to investigate the treatment effect upon the change in scores between baseline and after treatment, fitting treatment, period, Figure 1 Trial design. Schematic design of the study. After the screening, eligible patients were randomized. After that, the titration period of 3 weeks was followed by a treatment period of 8 weeks and ended by a tapering period of 2 weeks. After a washout period of at least 2 weeks, the same study periods took place with the different treatment. In addition to the visits at every new study period, there were regular telephone calls and patients filled in a daily pain diary from the first day of the study until the end.
interaction between treatment and period, subject baseline, period baseline, and the stratification factors as fixed effects. Subject was fitted as a random effect. Least squares (LS) means for the change from baseline with standard errors were calculated for each treatment, and the LS mean difference between the treatment groups was presented together with the 95% confidence interval (CI). The PGIC was analysed with a McNemar's test instead of the planned repeated measures analyses, because with the stricter definition, the placebo response was too sparse. All analyses and summaries were produced using SAS Õ version 9.2 (or higher). There was no imputation of missing data.
Data availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Results
Twenty-nine patients were screened for the study between November 2014 and July 2016 (Fig. 2) . Four of these patients were excluded, because of prohibited co-medication (n = 2), ECG abnormalities (n = 1), and non-compliance of scheduled appointments (n = 1). A total of 25 patients were randomized, with one patient dropping out directly after randomization but before treatment due to an accidental fall. This patient was excluded from further analyses because no post-baseline measurements were recorded. An additional patient dropped out during the washout period after the first treatment period, due to conflicting personal commitments, not related to the study medication. This patient was included in the analyses for the first period. Thus, 24 patients received lacosamide and 23 patients received placebo. Baseline characteristics are shown in Table 1 . Because of the trial design, the analyses of the primary and secondary outcomes were based on the whole group (n = 24). Therefore, differences between the groups based on baseline characteristics were not analysed. Figure 3 shows the average pain scores for each individual before and after treatment for the lacosamide and the placebo period. Figure 3A and B shows that average pain decreased more during the lacosamide period compared to the placebo period. The individual change in average pain scores before and after treatment for the two periods shows a larger significant decrease in patients using lacosamide compared to placebo. Figure 4 shows the weekly mean average pain for both groups in both treatment periods. The mean average pain of the patients that were using lacosamide was lower compared to the scores of the patients that used placebo during that time, which was the case in both treatment periods.
The proportion of responders for lacosamide and placebo was calculated from these data, and as the primary outcome shown in Table 2 . There was a significant effect of lacosamide on average pain compared to placebo. In the full analysis set there was a significant effect of lacosamide in a 51-point decrease of the mean average pain Figure 2 Trial profile. In total 29 patients were screened for the study. Four were excluded, because of using medication that acts on sodium channels (n = 2), because of ECG abnormalities (n = 1), and non-compliance of appointments (n = 1). In total, 25 patients were randomized, of which one patient dropped out directly after randomization due to an accidental fall. The patient was excluded from further analyses because no post-baseline measurements were recorded. An additional patient dropped out during the washout period after the first treatment period, due to personal circumstances not related to the study medication. This patient was included in the analyses for the first period. In total 24 patients received lacosamide and 23 patients received placebo.
(50.0% responder with lacosamide versus 21.7% placebo) with a P-value of 0.0231 and odds ratio (OR) of 4.45 (95% CI 1.38-14.36) and a trend towards an effect on a 52-point decrease of the average pain with a P-value of 0.0637 (25% responder with lacosamide versus 8.7% responder with placebo). In the sensitivity analyses both Mean day pain 6.4 (4-9) 6.6 (4-8) 6.5 (4-9) Mean night pain 5.7 (1-9) 5.5 (1-8) 5.6 (1-9) Mean average pain 6.2 (3-9) 6.1 (2-8) 6.1 (2-9) Max day pain 7.6 (6-9) 7.4 (5-10) 7.5 (5-10) Max night pain 6.7 (1-10) 7.0 (1-9) 6.8 (1-10) In A and B the average pain scores are shown before and after treatment for lacosamide and placebo, respectively (red lines). The mean change of the average pain is larger for the lacosamide period compared to the placebo period. Also, the change per subject before and after treatment is shown. More subjects have a decline, or a larger decline, during the use of lacosamide compared to placebo.
period 10 of 24 patients (41.67%) had a 30% reduction of the average pain from baseline, compared to 3 of 23 patients (13.04%) in the placebo period. In total 4 of 24 patients (16.67%) had a 50% reduction of the average pain, compared to 1 of 23 patients (4.35%) in the placebo group. A pathogenic gain-of-function mutation was found in 13 of 24 patients, while the other patients carried a variant that was not yet functionally confirmed. In the lacosamide period, 6 of 13 patients with a gain-of-function mutation (46.2%) had a 51-point decrease of the mean average pain and four patients (30.8%) had a 52-point decrease of the average pain [compared to 8 of 11 (72.7%) and 4 of 11 (36.4%), respectively, for the patients with the other variants]. In the placebo period, 3 of 13 patients with a gainof-function mutation (23.1%) had a 51-point decrease and 1 of 13 (7.7%) had a 52-point decrease of the mean average [compared to 2 of 10 (20.0%) and 1 of 10 (10.0%), respectively, for the patients with the other variants].
The secondary outcomes (Table 3) , showed similar results for the sensitivity analyses for the mean day pain, the mean night pain, the maximal night pain, and the mean average pain (as a continuous outcome). Only the maximal day pain showed no significant difference between lacosamide and placebo. There was also a significant decrease of the influence of pain on sleep quality, with a median value of the DSIS of 5.3 for the lacosamide period and 5.7 for the placebo period (least squares mean of À1.32 for lacosamide compared to least squares mean of À0.62 for placebo, with a least squares mean difference of À0.70). Also, the PGIC showed significant differences between the two groups, 33.3% of patients felt better during the use of lacosamide compared to 4.3% during the use of placebo (P-value of 0.0156). The NPS showed a significant effect of lacosamide on the intense surface pain (item 10b) (least squares mean of À1.27 for lacosamide compared to least squares mean of 0.03 for placebo, with a least squares mean difference of À0.70) but there was also a significant Figure 4 Weekly mean average pain during both treatment periods. The weekly mean average pain is shown for both groups in both treatment periods. The mean average pain of the patients that were using lacosamide was lower compared to the scores of the patients that used placebo during that time, which was the case in both treatment periods. BL = baseline; SD = standard deviation; W = week number. Lacosamide had a significant positive effect on mean day pain, mean night pain, maximal night pain, and mean average pain (as a continuous outcome). A significant decrease of the influence of pain on sleep quality in the lacosamide groups was demonstrated. The PGIC showed that 40% of patients felt better during the use of lacosamide compared to 13% during the use of placebo. The NPS showed a significant effect of lacosamide on intense surface pain, and a significant effect of placebo on the itchy feeling of pain. The sensitivity analyses set is the same as the full analyses set but without restrictions on baseline. DSIS = daily sleep interference scale; LS = least square estimate; PGIC = patients' global impression of change. *P-value below 0.05.
effect of placebo on the itchy feeling of pain (least squares mean of À0.24 for lacosamide compared to least squares mean of À1.00 for placebo, with a least squares mean difference of À0.76) compared to lacosamide. No significant differences were found for the SFN-SIQ sum score and the SF-36. Regarding safety, six serious adverse events (SAE) were reported (which were classified as serious because they required hospitalization), of which two occurred in the lacosamide period and four in the placebo period. The six SAE's were diplopia, vomiting, chest pain, conversion disorder, dyspnoea, and a bladder operation (which was requested by the patient because of complaints present prior to the start of the study). The adverse events that occurred in at least 5% in one of the two treatment groups are presented in Table 4 . The most frequent adverse events in the lacosamide period were dizziness, headache, and nausea, which were comparable to the most frequent adverse events in the placebo period.
During the study, 8 of 24 patients changed neuropathic pain medication, as shown in Supplementary Table 1 . Three patients changed medication during the placebo period. One patient decreased the medication during the lacosamide period, because of side effects, and increased them again during the placebo period, because of the return of pain. This patient was a responder during the lacosamide period, but not during the placebo period. One patient started medication during the lacosamide period and also during the placebo period, but was a non-responder in both periods. The other three patients started or increased their medication in the lacosamide period, two of them were responders for this period. 
Discussion
This is the first study that investigated the efficacy of lacosamide in patients with SFN. The results show that lacosamide significantly decreased pain and had a positive effect on sleep quality compared to placebo in patients with Na v 1.7-related SFN. Specifically, the surface pain intensity (item 10b of the NPS) was positively influenced. In addition, more than 33.3% of patients felt better (as reflected by the PGIC questionnaire) when using lacosamide. Compared with placebo, lacosamide appeared to be safe to use and well tolerated in this cohort of patients with SFN. The results are similar or even more positive compared to studies investigating the effect of lacosamide on neuropathic pain in painful diabetic neuropathy (Rauck et al., 2007; Shaibani et al., 2009; Wymer et al., 2009; Ziegler et al., 2010) . In contrast to those studies, however, the crossover design used in our study was chosen to provide reliable results despite small patient numbers. A recent study showed an effect of another Na v blocker, BIIB0074 on the pain attacks in patients with trigeminal neuralgia (Zakrzewska et al., 2017) .
Lacosamide appears to be as effective as currently available neuropathic pain treatment, with a response rate of 50-60%, which is at least comparable to the 50% of patients that have a reduction in pain intensity when treated with currently available therapeutics (Attal et al., 2010; Finnerup et al., 2015) . The factors underlying the variance in response to lacosamide are not known, but the variability in response possibly could be because of the different gene variants or epigenetic differences between patients. In this study, lacosamide showed a significant effect on the intensity of surface pain (item 10b on the NPS), which might suggest that lacosamide reduces the allodynic symptoms. At the moment, no accurate objective tools are available to test allodynia in the clinic; however, this would be of interest to test in future trials with lacosamide.
Our study did not show an effect of lacosamide on quality of life. The treatment period of 8 weeks was long enough to observe differences in pain intensity, but the duration of pain reduction might have been too short to result in a positive effect on quality of life. Another explanation for the absence of a significant change in quality of life could be that, in addition to neuropathic pain, other factors such as autonomic dysfunction might influence the quality of life of these patients. Na v 1.7 is expressed in both DRG neurons and sympathetic ganglion neurons, which explains the combination of neuropathic pain and dysautonomia in most patients with Na v 1.7 mutations . Based on this, lacosamide also might be expected to have a positive effect on autonomic complaints. However, it is known that mutated sodium channels can have a different effect on excitability, depending on the cell background, with some mutations having dramatically different effects on excitability of peripheral sensory versus sympathetic ganglion neurons (Rush et al., 2006; Han et al., 2012b) . The effect of lacosamide on Na v 1.7 within different subtypes of neurons, and its effect on excitability in different types of neurons, have not thus far been studied.
In this study, we did not see any changes in the SFN-SIQ, a questionnaire that also includes autonomic functions. A confounding factor could be the side effects that lacosamide can cause (like dizziness, dry eyes, or intestinal problems). It is not clear if these side effects are the result of central autonomic dysregulation, or due to a direct effect of lacosamide on the peripheral sympathetic neurons.
In the placebo group, a significant positive effect on the itchy feeling of pain was demonstrated. This is in line with previous research that showed a substantial placebo effect on itch in various dermatological conditions (van Laarhoven et al., 2015) .
The attenuation of pain that we observed is consistent with the mechanism of action of lacosamide. Lacosamide is thought to bind preferentially to Na v channels in the inactivated state (Rogawski et al., 2015; Jo and Bean, 2017) . Our previous studies have demonstrated spontaneous firing in dorsal root ganglion neurons expressing SFN-related Na v 1.7 mutations (Estacion et al., 2011; Faber et al., 2012; Han et al., 2012a) As a result of spontaneous activity in these neurons, which appears to contribute to pain, lacosamide would be expected to have a preferential effect on DRG neurons in SFN. As with other sodium channel blockers (e.g. phenytoin and carbamazepine) in epilepsy, the mechanistic bases for non-responsiveness of some patients are not fully understood.
The strength of the crossover design in our study was that fewer patients were required to obtain reliable results than in a parallel design, because each patient served as his/ her own matched control. The crossover design is justifiable because lacosamide was not being evaluated as a cure or a disease-modifying agent, but only a therapy for alleviating pain symptoms. It has been shown earlier that this design is useful for screening compounds for efficacy in proof-ofconcept studies with neuropathic pain (Ho et al., 2009) . The dosage used in this study (200 mg BID) was based on previous studies (Hearn et al., 2012; Zaccara et al., 2013) . At this dosage a significant effect was reached. In practice, for patients who did not respond on 200 mg BID, an increase of dosage to 300 mg BID might be considered, although the expected incidence of side effects increases with higher doses. Conversely, the dosage of lacosamide can be lowered to 100 mg or 150 mg BID when patients experience bothersome side effects.
This study has some potential limitations. First, as a result of the study design, a carryover effect could have occurred. This might confound direct treatment effects, because these effects cannot be estimated separately. This is minimized, however, because we implemented a washout period that was longer than the advised five (or more) half-life time lengths of the drug concentration in the blood (half-life of $13 h). In the mixed effects model analyses, no significant interaction was found between the treatment effect and the period effect, suggesting that there was no carry-over effect. This is confirmed by data in Fig. 4 , which show that the average pain scores return to the baseline in the washout period after the lacosamide arm. Thus, although the design is potentially open to carry-over effects, we found no evidence for such effects.
Second, the cohort that was investigated was relatively small and limited to patients carrying specific Na v 1.7 variants. SFN is rare and an SCN9A variant can be found in $9% (de Greef et al., 2018) . We chose this well-defined cohort, because our aim was to demonstrate proof-of-concept, which can be used for future studies involving larger groups of patients diagnosed with SFN. Since VGSCs also play a role in pathological neuropathic pain states even in the absence of mutations (Dib-Hajj et al., 2010) , a positive effect of lacosamide on pain in non-VGSC-mutation-related SFN is expected. After this study was started, the SFN-specific Rasch-built Overall Disability Scale (SFN-RODS) was developed (Brouwer et al., 2015a) . Besides the effect on neuropathic pain, this outcome measure can be of great value in future SFN studies to investigate the effect of lacosamide and other treatments on daily activity (Brouwer et al., 2015a) .
Third, the study was powered to find a difference between 60% response rate in the treatment period and 20% in the placebo period. However, the observed proportions were 58.3% and 21.7%, respectively, which was a little lower than expected. The results of this proof-of-concept study support further studies on lacosamide in patients with SFN.
Fourth, during this study, patients were allowed to continue using their current medications, when the dosage was stable for 30 days prior to screening and they did not inhibit sodium channels. Our data show that lacosamide can be prescribed as an effective add-on therapy. However, the quantities and types of concomitant medications differed between patients. Although we attempted to keep the use of concomitant medication as constant as possible, change was unavoidable in some cases, for example when patients suffered from side effects or severe pain. Therefore, no statements about interactions between lacosamide and other neuropathic painkillers can be made. In epilepsy it is known that lacosamide is more effective as a first addon drug compared to a later add-on treatment (Zadeh et al., 2015) . This might suggest that the effect of lacosamide might be even greater as a monotherapy or a first add-on treatment.
Finally, multiple Na v 1.7 variants were included in this study. Almost one-half of the patients with a pathogenic gain-of-function mutation were responders, which is comparable to the overall effect. Further research will be needed to see whether patients with some specific variants are to be more likely to respond to lacosamide compared to other variants. This could lead to more insight into why some patients derive benefit from lacosamide and some do not, and could lead to patient-specific treatments in the future.
In conclusion, this study provides evidence indicating that, in some patients with SFN, lacosamide can attenuate neuropathic pain. Specifically, our results show that lacosamide is well tolerated and safe, and can reduce neuropathic pain in Na v 1.7-related SFN.
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